南非暂停接种阿斯利康疫苗
南非宣布暂停接种阿斯利康(AZN.US)与牛津大学研发的新型冠状病毒疫苗。南非卫生部长Zweli Mkhize周日(7日)表示,根据一项初步研究,该款疫苗对南非变种新冠病毒引起的轻度或中度病徵预防力有限。在相关问题获得解决前,南非将暂停为医护人员接种阿斯利康疫苗。
阿斯利康早前指,一项小型试验的早期数据显示,其疫苗对预防南非变种毒株引起的轻微病徵效果有限,而试验受试者主要是健康的年轻人,因此目前还无法确定疫苗对预防新冠重症、住院和死亡的效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.